{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:06:37Z","timestamp":1789751197713,"version":"4.0.1"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,2,3]],"date-time":"2016-02-03T00:00:00Z","timestamp":1454457600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"None"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Neurovirol."],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s13365-016-0427-6","type":"journal-article","created":{"date-parts":[[2016,2,3]],"date-time":"2016-02-03T09:33:39Z","timestamp":1454492019000},"page":"533-535","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Reassessing the risk of natalizumab-associated PML"],"prefix":"10.1007","volume":"22","author":[{"given":"Joseph R.","family":"Berger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,3]]},"reference":[{"key":"427_CR1","unstructured":"Biogen. TYSABRI (natalizumab): PML Incidence in patients receiving TYSABRI [online]. Available at: http:\/\/medinfo.biogen.com . Accessed November 8, 2015."},{"key":"427_CR2","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","volume":"366","author":"G Bloomgren","year":"2012","unstructured":"Bloomgren G, Richman S, Hotermans C et al (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366:1870\u20131880","journal-title":"N Engl J Med"},{"key":"427_CR3","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/ene.12304","volume":"21","author":"C Bozic","year":"2014","unstructured":"Bozic C, Subramanyam M, Richman S, Plavina T, Zhang A, Ticho B (2014) Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial. Eur J Neurol 21:299\u2013304","journal-title":"Eur J Neurol"},{"key":"427_CR4","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1177\/1352458514531843","volume":"20","author":"GR Cutter","year":"2014","unstructured":"Cutter GR, Stuve O (2014) Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence? Mult Scler 20:1304\u20131305","journal-title":"Mult Scler"},{"key":"427_CR5","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1212\/WNL.0b013e318245d2d0","volume":"78","author":"RJ Fox","year":"2012","unstructured":"Fox RJ, Rudick RA (2012) Risk stratification and patient counseling for natalizumab in multiple sclerosis. Neurology 78:436\u2013437","journal-title":"Neurology"},{"key":"427_CR6","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","volume":"76","author":"T Plavina","year":"2014","unstructured":"Plavina T, Subramanyam M, Bloomgren G et al (2014) Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 76:802\u2013812","journal-title":"Ann Neurol"},{"key":"427_CR7","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa054693","volume":"354","author":"TA Yousry","year":"2006","unstructured":"Yousry TA, Major EO, Ryschkewitsch C et al (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354:924\u2013933","journal-title":"N Engl J Med"}],"updated-by":[{"DOI":"10.1007\/s13365-016-0431-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2016,3,29]],"date-time":"2016-03-29T00:00:00Z","timestamp":1459209600000}}],"container-title":["Journal of NeuroVirology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-016-0427-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13365-016-0427-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-016-0427-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T12:08:38Z","timestamp":1559477318000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13365-016-0427-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,3]]},"references-count":7,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["427"],"URL":"https:\/\/doi.org\/10.1007\/s13365-016-0427-6","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s13365-016-0431-x","asserted-by":"object"}]},"ISSN":["1355-0284","1538-2443"],"issn-type":[{"value":"1355-0284","type":"print"},{"value":"1538-2443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,3]]}}}